Silence Therapeutics has been granted a patent for nucleic acid products designed to inhibit target gene expression. The invention includes specific structural features of the nucleic acids, such as duplex regions and inverted nucleotides, aimed at therapeutic applications in gene regulation. GlobalData’s report on Silence Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Silence Therapeutics, was a key innovation area identified from patents. Silence Therapeutics's grant share as of June 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Nucleic acid for inhibiting target gene expression
The patent US11987794B2 describes a novel nucleic acid designed to inhibit the expression of a target gene within a cell. The nucleic acid comprises a duplex region formed by a first strand and a second strand, each ranging from 17 to 35 nucleotides in length. The first strand is complementary to a portion of the RNA transcribed from the target gene. Notably, the terminal nucleotides at either the 3' or 5' ends of the strands are inverted ribonucleotides, which are linked to adjacent nucleotides through their respective carbon atoms. The patent also outlines various modifications that can be made to the nucleotides, including 2'-O-methyl or 2'-F modifications, and the potential inclusion of ligands, such as GalNac, to enhance the nucleic acid's functionality.
Additionally, the patent claims methods for utilizing this nucleic acid in therapeutic applications, including the treatment of diseases or disorders through the administration of a composition containing the nucleic acid and a physiologically acceptable excipient. The claims further specify variations in the structure of the nucleic acid, such as blunt ends, overhangs, and the specific types of inverted nucleotides that can be employed. This innovative approach to gene inhibition may have significant implications for targeted therapies in genetic and molecular medicine.
To know more about GlobalData’s detailed insights on Silence Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
